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Abstract
Purpose Dabigatran is effective for both the prevention of
stroke and bleeding in patients with atrial fibrillation (AF).
However, the safety and efficacy of the use of dabigatran in
the peri-procedural period for radiofrequency catheter abla-
tion (RFCA) of AF is unknown. Therefore, the purpose of
this study was to evaluate the safety and efficacy of
dabigatran in the peri-procedural period for RFCA of AF
and the duration of hospital stay.
Methods Consecutive patients (n=227) who underwent
RFCA for AF were prospectively analyzed. Peri-
procedural anticoagulant therapy with dabigatran (n=101,
D group) was compared with warfarin and heparin bridging
(n=126, W group). Dabigatran was discontinued 12–24 h
before and restarted 3 h after the procedure. Warfarin was
stopped 3 days before the procedure and unfractionated
heparin was administered.
Results Ischemic stroke occurred in one patient of the D
group (0.8 %). There was no significant difference between
the two groups in the incidence of major bleeding (three cases
of cardiac tamponade in each group and one case of intracra-
nial bleeding in the W group, p=0.93) or minor bleeding (five
cases in the D group vs. five in the W group, p=0.54). The
duration of hospital stay was significantly shorter in the D
group than in the W group (7.2 vs. 10.3 days, p=0.0001).
Conclusions Peri-procedural anticoagulation therapy with
dabigatran for RFCA of AF was equally safe and effective
compared with warfarin and heparin bridging. The use of
dabigatran for RFCA of AF shortened the duration of hos-
pital stay.
Keywords Atrial fibrillation . Catheter ablation .
Dabigatran . Complications . Duration of hospital stay
1 Introduction
Dabigatran, a new oral direct thrombin inhibitor, has been
reported to be safe and effective for the prevention of stroke
in patients with atrial fibrillation (AF). Dabigatran 150 mg
twice daily reduced both stroke and intracranial and life-
threatening bleeding; dabigatran 110 mg twice daily was not
inferior to warfarin for reducing the risk of stroke but
significantly reduced intracranial, life-threatening, and ma-
jor bleeding [1–3]. Based on the results of these clinical
trials, it is likely that the frequency of dabigatran use will
increase in the future.
It is well known that radiofrequency catheter ablation
(RFCA) is an effective treatment for drug-refractory AF,
and peri-procedural anticoagulation is particularly important
to prevent thromboembolic events [4]. However, the peri-
procedural anticoagulation protocol varies among centers
[5]. Most centers discontinue warfarin (Coumadin) at least
3 to 5 days prior to RFCA and initiate heparin before the
procedure as a “bridging strategy.”Warfarin is restarted after
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the procedure and heparin is discontinued after therapeutic
international normalized ratio (INR) is attained. Recently,
some centers have continued warfarin during the procedure
to maintain the INR within the therapeutic range [6–8].
Some studies reported that the use of dabigatran in the
peri-procedural period for RFCA of AF was effective and
safe, but one study reported that peri-procedural dabigatran
use increased the risk of thromboembolism and bleeding
[9–11]. Thus, the efficacy and safety of dabigatran in the
peri-procedural period remains controversial.
It is assumed that the dabigatran would shorten the length
of hospital stay compared with the heparin bridging strategy
because hospitalization is required at least 3 to 5 days before
ablation to initiate heparin therapy in the country where
subcutaneous enoxaparin is not available.
In this study, we compared dabigatran with warfarin and
heparin bridging in terms of efficacy and safety during the
peri-procedural period for RFCA of AF. In addition, we
compared the total duration of hospital stay between these
two anticoagulation strategies.
2 Methods
Between April 2011 and November 2012, 227 consecutive
patients who underwent RFCA of AF (165 males, 62±
9 years old, paroxysmal AF (n=119)) were prospectively
analyzed. Peri-procedural anticoagulation therapy with
dabigatran (n=101, D group) was compared with warfarin
and heparin bridging (n=126, W group). Patients were
divided into two groups based on the discretion of the
physician and the hope of patients. The exclusion criteria
was age >80 years in both groups. In the D group, reasons
for exclusion were the presence of severe heart valve disor-
der. All patients were evaluated for complications related to
the procedure at the time of hospitalization and during
subsequent follow-up visits up to 1 month after RFCA.
Major bleeding complications were defined as the occur-
rence of cardiac tamponade, intracranial bleeding, fatal
bleeding, any bleeding that resulted in a significant decrease
in hemoglobin (≥2 g/dl) or required transfusion or interven-
tion, or hematoma that required surgery or transfusion.
Minor bleeding complications were defined as the occur-
rence of hematoma or any bleeding that did not require
surgery or transfusion.
Thromboembolic complications were defined as the oc-
currence of ischemic stroke, transient ischemic attack, or
peripheral embolic events. Stroke was defined as the sudden
onset of a focal neurologic deficit.
The duration of hospital stay was also compared between
the two groups.
The distribution of activated partial thromboplastin time
(aPTT) values, which provides a useful qualitative
assessment of anticoagulant activity [12–14], was analyzed
in the D group during the peri-procedural period.
2.1 Electrophysiological study and ablation protocol
All patients had anticoagulation for ≥1 month and
transesophageal echocardiography was performed to ex-
clude atrial thrombus before the procedure. All antiarrhyth-
mic medications were stopped four to five half-lives before
RFCA, except for amiodarone, which was stopped 1 month
before the procedure. Two 8-Fr sheaths, one 8.5-Fr Agilis
sheath, one 10.5-Fr sheath, and one 6-Fr sheath were
inserted in the femoral vein. One 6-Fr sheath was inserted
in the right internal jugular vein or left subclavian vein.
Transseptal punctures were performed guided by intracardi-
ac echocardiography (ICE). Pulmonary venous and left atri-
al angiography was performed and a 3-dimensionsal
geometrical map of the atria and pulmonary veins (PVs)
was created using the Ensite NavX® mapping system (St.
Jude Medical, Minneapolis, MN). Intravenous heparin was
administered immediately after atrial transseptal puncture to
maintain an activated clotting time (ACT) of >300 s. The
ACT levels were monitored every 30 min and additional
heparin was injected as necessary to maintain an ACT of
>300 s. PV mapping was performed with a steerable circular
catheter of 20, 25, or 30 mm in diameter (Lasso, Biosense
Webster, Diamond Bar, CA). A 3.5-mm-tip irrigation cath-
eter (Coolpath Duo, St. Jude Medical, Minneapolis, MN) or
8-mm-tip ablation catheter (Fantasista, Japan Lifeline, To-
kyo, Japan) was selected as the roving and ablation catheter.
Encircling PV isolation (PVI) was performed with the NavX
mapping system and double-Lasso technique [15, 16]. The
radiofrequency energy output was titrated to 30–35 Walong
the anterior line and 20–25 W during ablation of the poste-
rior area. After successful isolation of all PVs, high-dose
isoproterenol (5–20 μgmin−1h−1) was administered to in-
duce AF. When non-PV foci that could initiate AF were
detected, focal ablation was performed. If the non-PV foci
originated in the superior vena cava (SVC), segmental iso-
lation of the SVC was performed [17, 18]. After PVI and
non-PV foci ablation, burst atrial pacing was performed
from four sites: the proximal coronary sinus (CS), distal
CS, high right atrium, and left atrial appendage (LAA).
Pacing was initiated at a cycle length of 250 ms and de-
creased in 10 ms decrements to the shortest cycle length that
allowed 1:1 atrial capture. When typical atrial flutter was
induced during burst pacing, cavotricuspid isthmus ablation
was performed. We did not perform adjunctive ablation for
inducible AF or atrial tachycardia in paroxysmal AF pa-
tients. However, additional ablation lines or ablation of re-
gions with complex fractionated atrial electrograms was
performed in persistent AF patients based on the discretion
of the operator.
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Light to moderate sedation was used during the procedure.
For external cardioversion, transient deep sedation was used.
2.2 Anticoagulation
We used two doses of dabigatran (220 or 300 mg/day)
depending on the patient’s condition. A low dose of dabigatran
(220 mg/day) was administered to patients who had one or
more of the following conditions: co-administration of potent
permeability glycoprotein inhibitors (amiodarone, verapamil,
or quinidine) or antiplatelet drugs, renal dysfunction (CCr, 30–
50 ml/min), past history of upper gastrointestinal ulcer, or
advanced age (≥70 years old) [1, 19–23].
The anticoagulation protocol in the peri-procedural period
is shown in Fig. 1. In the D group, the patients were admitted
1 day before the procedure and the timing of discontinuation
of dabigatran before RFCA was adjusted depending on the
thromboembolic risk. Dabigatran was discontinued 24 h be-
fore ablation in patients with paroxysmal AF and a CHADS2
score of 0 or 1 [24]. In patients with a high thromboembolic
risk (CHADS2 score of ≥2 or persistent AF), dabigatran was
stopped 12 h before ablation. In the W group, warfarin was
stopped 3 days before RFCA and unfractionated heparin was
administered to maintain an aPTT of 2.0 to three times the
control value. Heparin was stopped 3 h before the procedure.
In both groups, heparin was administered during the
procedure to keep ACT in the range of 300 to 350 s. Imme-
diately after the procedure, heparin was stopped and prot-
amine (20–30 mg) was administered to partially reverse
heparin-induced anticoagulation. Then, all sheaths were re-
moved. In the D group, dabigatran was restarted 3 h after
ablation and patients were discharged 3 days after ablation. In
the W group, heparin and warfarin were restarted 3 h after
ablation. After a therapeutic INR was attained, heparin was
stopped and the patients were discharged.
2.3 Follow-up
All patients were followed up for 1 month before and
1 month after ablation and evaluated for complications.
Some patients in the W group were followed by local
doctors to maintain a therapeutic INR. During the 1-month
visit after ablation, the recovery progress and any compli-
cations including those related to the procedure were
reviewed and recorded.
2.4 Statistical analysis
All continuous variables are expressed as the mean±SD. All
categorical variables are reported as the number
(percentage) of patients. SPSS version 18.0 (SPSS Inc.,
Chicago, IL) was used for all statistical analyses. A student’s
Fig. 1 This figure displays our
algorithm for peri-procedural
anticoagulation in patients
treated with dabigatran or
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t test was used to compare continuous variables. A p value
of <0.05 was considered significant.
3 Results
3.1 Clinical and procedural characteristics
The demographics and clinical characteristics of the patients
are summarized in Table 1. The mean age was 62±9 years.
Men accounted for 72.7 % of the patients. The AF type was
paroxysmal in 119(52.4 %) patients and nonparoxysmal in
107 (47.6 %) patients. The CHADS2 score was 0 in 75 (33.
0 %), 1 in 105 (46.3 %), and ≥2 in 47 (20.7 %). There were
no differences in the clinical and procedural characteristics
between the two groups (Tables 1 and 2).
3.2 Anticoagulation
The reason for reducing the dose and the timing of discon-
tinuation of dabigatran before ablation were shown in
Table 3.
We analyzed shifting of the aPTT distribution during
the peri-procedural period in the D group (Fig. 2). The
aPTT value at the peak ranged widely from 32 to 73 s
and was ≥70 s in six patients, five of whom were
female. The aPTT value at the trough dabigatran levels
ranged from 33 to 47 s before ablation. After
dabigatran was discontinued, the aPTT decreased and
the mean aPTT just before ablation was 34 s. After
dabigatran was restarted, the aPTT value at the trough
gradually increased and reached a plateau 3 days after
ablation.
Table 1 Clinical characteristics of the patient population
All patients (n=227) D group (n=101) W group (n=126) p value
Age (years) 62±9 61±10 62±8 0.33
Male (n; %) 165 (72.7) 76 (75.2) 89 (70.6) 0.46
AF history (months) 56±72 48±59 63±80 0.10
AF type, paroxysmal (n; %) 119 (52.4) 57 (56.4) 62 (49.2) 0.29
CHADS2 score 1.0±0.9 0.9±0.9 1.1±1.0 0.22
CHA2DS2-VASc score 1.7±1.2 1.6±1.2 1.8±1.2 0.11
HAS-BLED score 0.9±0.8 0.7±0.8 1.0±0.9 0.16
Heart failure (n; %) 38 (16.7) 15 (14.9) 23 (18.3) 0.59
Hypertension (n; %) 121 (53.3) 48 (47.5) 73 (57.9) 0.14
Age >75 years (n; %) 8 (3.6) 3 (3.0) 5 (3.9) 0.47
Diabetes mellitus (n; %) 24 (10.6) 10 (9.9) 14 (11.1) 0.83
Prior Stroke/TIA (n; %) 16 (7.0) 6 (5.9) 10 (7.9) 0.61
Coronary artery disease (n; %) 12 (5.3) 6 (5.9) 6 (4.8) 0.77
Antiarrhythmic drugs (n; %) 187 (82.4) 83 (82.1) 105 (83.4) 0.92
Class I group (n; %) 142 (62.6) 65 (64.4) 77 (61.1) 0.45
Bepridil (n; %) 40 (17.6) 17 (16.8) 23 (18.3) 0.86
Amiodarone (n; %) 6 (2.6) 1 (1.0) 5 (4.0) 0.07
Aspirin/antiplatelet drugs (n; %) 17 (7.5) 8 (7.9) 9 (7.1) 0.99
Verapamil (n; %) 48 (21.1) 19(18.8) 29 (23.0) 0.51
Beta blocker (n; %) 92 (40.5) 34 (33.7) 58 (46.0) 0.07
ACE-I/ARB (n; %) 90 (39.6) 36 (35.6) 54 (42.9) 0.28
Diuretics (n; %) 28 (12.3) 9 (8.9) 19 (15.1) 0.22
Left atrial diameter (mm) 42±7 41±7 42±7 0.40
LV ejection fraction (%) 63±9 63±8 62±9 0.36
Mitral regurgitation 1.5±0.7 1.4±0.6 1.5±0.7 0.21
Flow velocity in LAA (cm/s) 49±24 51±26 48±23 0.36
SEC (n; %) 37 (16.3) 18 (17.8) 19 (15.1) 0.59
Creatinine (mg/dl) 0.8±0.2 0.8±0.2 0.8±0.2 0.42
CCr (ml/min) 88±22 89±25 87±20 0.55
30–50 (ml/min; n; %) 4 (1.7) 0 (0) 4 (3.3) 0.19
AF atrial fibrillation, TIA transient ischemic attacks, LAA left atrial appendage, LV left ventricle, SEC spontaneous contrast echo, CCr creatinine
clearance
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3.3 Complications
Details of complications in the peri-procedural period are
shown in Table 4. There were no deaths in this study. A total
of 18 (7.9 %) patients had either bleeding or thromboem-
bolic complications.
3.4 Bleeding complications
Overall bleeding complications occurred in 17 (7.5 %) pa-
tients, and seven (3.1 %) had major bleeding.
The major bleeding complications were six cases of cardiac
tamponade that required pericardiocentesis and one case of
intracranial bleeding. Pericardiocentesis was performed suc-
cessfully and hemodynamic function was immediately re-
stored in the majority of patients. No patient required
surgery. One patient in each group needed a transfusion due
to hypotension from cardiac tamponade. One case of intracra-
nial bleeding occurred before RFCA in the W group. This
patient was a 75-year-old male who had symptomatic drug
refractory paroxysmal AF with heart failure. His CHADS2
score was 2 (congestive heart failure and hypertension), his
CHA2DS2-VASc score was 5 and his HAS-BLED score
was 3 (hypertension, elderly, and antiplatelet drugs). Dual
antiplatelet therapy (aspirin and clopidogrel) had been ini-
tiated for coronary artery disease after implantation of
drug-eluting stents. He complained of left hemiparalysis
2 days before the procedure during heparin bridging and
was diagnosed with right putaminal hemorrhage by brain
plane CT. An emergency craniotomy was performed for
removal of the hematoma and continuous ventricular drain-
age; however, a mild disturbance of consciousness and left
hemiparalysis remained.
Most of the minor bleeding events were oozing from the
puncture sites in the femoral vein. There was no significant
difference in major bleeding complications (3 (3.0 %) events
in the D group vs. 4 (3.2 %) events in the W group, p=0.93)
and minor bleeding (5 (5.0 %) events in the D group vs. 5
(4.0 %) events in the W group, p=0.54).
Table 2 Procedural characteris-
tics in both groups
RF radiofrequency, PV pulmo-
nary vein, AFL atrial flutter
D group (n=101) W group (n=126) p value
Rhythm just before ablation sinus rhythm (n; %) 36 (36) 51 (40) 0.49
Procedure time (min) 253±54 267±57 0.09
Fluoroscopy time (min) 94±22 99±25 0.13
RF time (min) 48±16 52±17 0.07
Use of irrigation catheter (n; %) 94 (90) 108 (84) 0.09
Cardioversion during procedure (n; %) 69 (68) 94 (75) 0.30
Mean number of cardioversion 1.5±1.4 1.8±1.8 0.12
PV isolation (n; %) 101 (100) 125 (99) 0.98
Non-PV foci ablation (n; %) 8 (8) 18 (14) 0.15
Common AFL ablation (n; %) 38 (38) 40 (32) 0.40
Adjunctive therapy (n; %) 11 (10) 29 (23) 0.55
Table 3 The reason for reducing the dose and the timing of discon-
tinuation of dabigatran before ablation
D group (n=101)
The reason for reducing the dose
Verapamil (n; %) 17 (17)
Amiodarone (n; %) 1 (1)
Aspirin/antiplatelet (n; %) 7 (7)
Renal dysfunction (n; %) 0 (0)
Age >70 years (n; %) 24 (24)
Upper gastrointestinal ulcer 2 (2)
Total (n; %) 45 (45)
The timing of discontinuation of dabigatran before ablation
24 h before ablation (n; %) 48 (48)
12 h before ablation (n; %) 53 (52) Fig. 2 Shifting of APTT distribution in the dabigatran group. APTT
activated partial thromboplastin time
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3.5 Thromboembolic complications
One thromboembolic complication occurred in the D group. He
was a 73-year-old male with persistent AF, a CHADS2 score of
0 and a CHA2DS2-VASc score of 1 [25]. His dose of dabigatran
was reduced to 220 mg/day considering his advanced age and
the co-administration of aspirin due to coronary artery disease.
His left atrial diameter was relatively large (41, 77, and 51 mm
in the parasternal, sagittal, and horizontal echo views, respec-
tively). The flow velocity in the LAA was low (18 cm/s) and
very strong spontaneous echo contrast was observed by
transesophageal echo before ablation and ICE during the pro-
cedure. PVI and cavotricuspid isthmus ablation were
performed successfully by the irrigated ablation catheter. Right
side of medial longitudinal fasciculus syndrome (MLF syn-
drome: disorder of the coordination and synchronization of all
major classes of eye movements and partial unconsciousness)
occurred on the next day after the procedure, and multiple
cerebral infarctions were suspected based on MRI. Fortu-
nately, his neurologic symptoms resolved completely the
day after the event.
3.6 Other complications
In the D group, six (5.9 %) patients complained of dyspepsia
after starting dabigatran that improved or resolved by oral
intake of a proton pump inhibitor without stopping the
dabigatran, there was one case of sick sinus syndrome
(SSS) that required permanent pacemaker and one case of
phrenic nerve palsy. Other complications in the W group
included the following: one case of congestive heart failure,
one case of SSS that required temporary pacing, two cases
of pericarditis, one case of acute paralytic gastric dilatation
and one case of urinary tract infection.
3.7 Duration of hospital stay
The duration of hospital stay was significantly shorter in the D
group than in the W group (7.2±2.0 vs. 10.3±3.9 days, p=0.
0001; Table 4). The main reason was the absence of heparin
bridging in the peri-procedural period in the D group.
4 Discussion
We compared dabigatran with warfarin and heparin bridging
in the peri-procedural period for RFCA of AF. There was no
significant difference in bleeding complications or thrombo-
embolism between the two groups; however, the use of
dabigatran significantly shortened the duration of hospital
stay. Dabigatran is an oral direct thrombin inhibitor and its
anticoagulant effect in plasma is achieved within 2–3 h of
ingestion. In the RE-LY trial, a dabigatran dose of 300 mg/day
was superior to warfarin with regard to stroke prevention in
patients with nonvalvular AF, and a 220 mg/day dose of
dabigatran was not inferior to warfarin [1, 2]. The morbidity
of AF is increasing worldwide, and dabigatran is expected to
be prescribed more frequently in the future. In this study, we
demonstrated the efficacy and safety of dabigatran in the peri-
procedural period for RFCA of AF.
4.1 Anticoagulation strategy
Discontinuation of warfarin 3 to 5 days before RFCA and
use of heparin or enoxaparin as a “bridging strategy” is the
most frequently used anticoagulation protocol in AF pa-
tients undergoing RFCA [4, 26]. Recently, it was shown
that continuation of warfarin at a therapeutic INR during the
peri-procedural period was effective and safe [7, 8, 27]. The
disadvantage of continuation of warfarin is that in cases with
major bleeding complications such as cardiac tamponade or
intracranial hemorrhage, it takes a long time for vitamin K to
fully antagonize warfarin. In contrast, anticoagulation with
heparin is easily induced and can be immediately reversed
with protamine. Therefore, heparin bridging is often used in
many low-volume centers or by inexperienced operators.
Dabigatran is rapidly absorbed and anticoagulation oc-
curs rapidly within 2–3 h. The mean terminal half-life of
Table 4 Complications after
ablation and duration of hospital
stay
D group dabigatran, W group
warfarin, TIA transient ischemic
attack
D group (n=101) W group (n=126) p value
Thromboembolic complication (n; %) 1 (1.0) 0 (0) 0.45
Stroke/TIA (n; %) 1 (1.0) 0 (0) 0.45
Systemic embolism (n; %) 0 (0) 0 (0)
Major bleeding complication (n; %) 3 (3.0) 4 (3.2) 0.93
Cardiac tamponade (n; %) 3 (3.0) 3 (2.4) 0.78
Intracranial bleeding (n; %) 0 1 (0.8) 0.37
Fatal bleeding (n; %) 0 0
Minor bleeding complication (n; %) 5 (5.0) 5 (4.0) 0.54
Others (n; %) 8 (7.9) 6 (4.8) 0.33
Duration of hospital stay (days) 7.2±2.0 10.3±3.9 0.0001
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dabigatran is 8 h after a single dose and ranges from 12 to14
h after multiple doses [28]. Thus, we adjusted the timing of
discontinuation of dabigatran before RFCA depending on
the thromboembolism risk. Dabigatran was discontinued
24 h before ablation in the patients with paroxysmal AF
and a CHADS2 score of 0 or 1. In patients with high
thromboembolic risk (CHADS2 score of ≥2 or persistent
AF), dabigatran was stopped 12 h before RFCA, and the
procedure was performed after one dabigatran half-life.
Dabigatran was restarted 3 h after ablation. This protocol
might reduce bleeding and thromboembolic risk.
In this study, aPTT tests were performed at the time of
dabigatran administration (peak), the next morning (trough),
just before ablation, and at 1 and 3 days after RFCA. The
peak aPTT was >70 s in some patients with smaller body
weight (<45 kg) or females. The dose of dabigatran should
be reduced in conditions such as the co-administration of
potent permeability glycoprotein inhibitors (amiodarone,
verapamil, or quinidine), antiplatelet drugs, or renal dys-
function. It was recently reported that high aPTT value
correlated with bleeding events [3], and it might be neces-
sary to check the aPTT value before ablation. The dose of
dabigatran may need to be reduced in patients with advance
age, smaller body weight, or a high aPTT value.
4.2 Bleeding and thromboembolic complications
In three previous studies, the incidence of major and minor
bleeding complications and thromboembolic complications
after RFCA of AF in the peri-procedural period were 0.3–
12.2, 0.79–20.0, and 0.1–1.1 %, respectively [7, 27, 29].
The incidence of bleeding and thromboembolism were
influenced by various factors, such as patient characteristics,
the size of the puncture needle and sheath, the method of
transseptal puncture, the value of aPTT during the proce-
dure, the type of ablation catheter, and the RF time [30–33].
In this study, the incidence of major and minor bleeding
complications was similar to those in previous studies and
were not significantly different between the D and W
groups. One thromboembolic event with full recovery oc-
curred in the D group. In this case, the reason for cerebral
thromboembolism may have been related to strong sponta-
neous echo contrast in the LAA, a low LAA flow [32, 34]
and persistent AF. The 3 h delay to the restart of dabigatran
after the procedure may have been too long and protamin at
the time of removal of the sheaths should not be adminis-
trated in such high-risk patients. One case of intracranial
bleeding occurred 2 days before RFCA during heparin
bridging in the W group. The CHA2DS2-VASc score and
HAS-BLED score were relatively high in this patient, and
the main reason for bleeding was unnecessary triple
antithrombotic therapy (aspirin, clopidogrel, and warfarin).
Clopidogrel should have been discontinued at least before
RFCA because a drug-eluting stent had been implanted
5 years ago. In cases of cardiac tamponade or excessive
bleeding, there is no specific antidote at present for
dabigatran. However, the use of fresh frozen plasma, pro-
thrombin complex concentrates, or hemodialysis might be
helpful [32, 34].
Several studies have been published on the use of
dabigatran in the peri-procedural period. Winkle et al. [11]
reported that dabigatran is an alternative to anticoagulation
with warfarin before and after AF ablation, but their study
had a relatively small sample size. Lakkireddy et al. [10]
reported that peri-procedural dabigatran use increases the
risk of bleeding and thromboembolic complications. These
two previous studies differ from ours in the timing of dis-
continuation of dabigatran. More recently, Kaseno et al. [9]
showed that a 220 mg/day dose of dabigatran was safe for
AF ablation in patients with a relatively low risk of throm-
boembolism, and their study differs from ours in the dose of
dabigatran administered. We adjusted the timing of
dabigatran administration (12 or 24 h) before RFCA
depending on the thromboembolic risk and reduced the dose
of dabigatran depending on the patient’s condition (co-ad-
ministration of amiodarone, verapamil antiplatelet drugs,
past history of upper gastrointestinal ulcer, or advanced
age). This protocol could reduce the risk of bleeding and
thromboembolic events.
4.3 The duration of hospital stay
In this study, the duration of hospital stay was significantly
shorter in the D group than in the W group. There are no
previous studies that evaluated the duration of hospital stay
in RFCA of AF. However, the duration of hospital stay may
be not different when RFCA of AF is performed without
discontinuation of warfarin and heparin bridging. In the
areas where subcutaneous enoxaparin is available in the
procedural period of RFCA for AF, the short time hospital-
ization by the use of dabigatran may not have major advan-
tage compared with heparin bridging strategy. However, the
use of dabigatran surrounding AF ablation (stopped 12–24 h
before the procedure and restart 3 h after the procedure) is
thought to be more simple and easier methods compared
with heparin bridging strategy. There is improved cost-
effectiveness of dabigatran compared with warfarin [35,
36], and many patients may undergo RFCA of AF under
dabigatran in the future.
4.4 Limitations
Although there was only one stroke event in the D group,
our study was a relatively small observational study, and
RFCAwas done in only a single center. A larger randomized
trial would be required to determine if dabigatran is not
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inferior to warfarin with heparin bridging in the point of
thromboembolic risk. Another limitation was that none of
the patients in the D group had a low CCr (30–50 ml/min).
We had no experience with patients who had renal failure in
the peri-procedural period.
5 Conclusions
Peri-procedural anticoagulation therapy with dabigatran for
RFCA of AF was equally safe and effective against warfarin
and heparin bridging strategy. The use of dabigatran for AF
in the peri-procedural period shortened the duration of hos-
pital stay. Further studies are needed to evaluate the
noninferiority of dabigatran compared with warfarin and
heparin bridging strategy.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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